Vertex Pharmaceuticals Inc Stock Forecast for 2023 - 2025 - 2030

Updated on 03/22/2023

Stock Rating
16
Price Target
$326.00
Consensus
Outperform
Upside
7.71%
Analysts
18
Stock Rating
16
Upside
7.71%
Analysts
18
Price Target
$326.00

Vertex Pharmaceuticals Inc Stock Forecast and Price Target

The average target price for Vertex Pharmaceuticals Inc's stock set by eighteen renowned analysts in recent months is $326.00, representing a potential upside of approximately 7.71% from its last closing price if met by 2024. This estimation is based on a high estimate of $440.00 and a low estimate of $280.00. Even if you are not interested in VRTX stock, it is still imperative to be aware of its competitors.

$326.00

7.71% Upside

Outperform
Outperform

Vertex Pharmaceuticals Inc Fair Value Forecast for 2023 - 2025 - 2030

In the last two years, Price for Vertex Pharmaceuticals Inc has grown by 144.28%, going from $148.28 to $362.22. In the coming year, analysts are expecting an increase in Fair Value, predicting it will reach $432.60 – an increase of 19.43%. Over the next eight years, experts anticipate that Fair Value growth for Vertex Pharmaceuticals Inc will be 74.58%.

2023 Fair Value Forecast
$432.60
2024 Fair Value Forecast
$448.46
2025 Fair Value Forecast
$483.51
2026 Fair Value Forecast
$518.56
2027 Fair Value Forecast
$532.20
2028 Fair Value Forecast
$565.30
2029 Fair Value Forecast
$597.30
2030 Fair Value Forecast
$632.35
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
JNJ Stock Forecast Johnson & Johnson Outperform 10
$153.96 Buy/Sell $181.05 17.24%
LLY Stock Forecast Eli Lilly and Outperform 16
$331.08 Buy/Sell $333.19 20.82%
PFE Stock Forecast Pfizer Inc Outperform 3
$40.66 Buy/Sell $53.97 29.49%
MRK Stock Forecast Merck Outperform 5
$105.62 Buy/Sell $99.57 11.72%
BMY Stock Forecast Bristol-Myers Squibb Co Outperform 2
$67.52 Buy/Sell $80.99 22.93%

Vertex Pharmaceuticals Inc Revenue Forecast for 2023 - 2025 - 2030

In the last two years, Revenue for Vertex Pharmaceuticals Inc has grown by 81.95%, going from $4.16B to $7.57B. In the coming year, analysts are expecting an increase in Revenue, predicting it will reach $9.24B – an increase of 21.94%. Over the next eight years, experts anticipate that Revenue growth for Vertex Pharmaceuticals Inc will be 69.63%.

2023 Rev Forecast
$9.24B
2024 Rev Forecast
$9.72B
2025 Rev Forecast
$10.41B
2026 Rev Forecast
$11.03B
2027 Rev Forecast
$11.38B
2028 Rev Forecast
$11.90B
2029 Rev Forecast
$12.41B
2030 Rev Forecast
$12.85B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
REGN Stock Forecast Regeneron Pharmaceuticals Inc Outperform 2
$759.81 Buy/Sell $796.73 2.92%
ZTS Stock Forecast Zoetis Outperform 18
$166.35 Buy/Sell $209.70 23.23%
BAX Stock Forecast Baxter International Inc Outperform 17
$39.62 Buy/Sell $60.73 46.39%

Vertex Pharmaceuticals Inc Dividend per Share Forecast for 2023 - 2025 - 2030

2023 DPS Forecast
$0.00
2024 DPS Forecast
$0.00
2025 DPS Forecast
$0.00
2026 DPS Forecast
$0.00
2027 DPS Forecast
$0.00
2028 DPS Forecast
$0.00
2029 DPS Forecast
$0.00
2030 DPS Forecast
$0.00
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
ALNY Stock Forecast Alnylam Pharmaceuticals Inc Outperform 7
$190.34 Buy/Sell $244.18 31.87%
VTRS Stock Forecast Viatris Hold 8
$9.44 Buy/Sell $13.70 43.01%
UTHR Stock Forecast United Therapeutics Outperform 12
$222.34 Buy/Sell $280.69 32.68%

Vertex Pharmaceuticals Inc Free Cash Flow Forecast for 2023 - 2025 - 2030

In the last two years, Vertex Pharmaceuticals Inc's Free Cash Flow has grown, increasing from $1.49B to $2.41B – an increase of 61.22%. For next year, the 7 analysts predict Free Cash Flow of $3.84B, which would mean an increase of 59.44%. Over the next eight years, the pros' prediction is Free Cash Flowof $6.40B, which would mean a eight-year growth forecast of 165.57%.

2023 FCF Forecast
$3.84B
2024 FCF Forecast
$4.17B
2025 FCF Forecast
$4.44B
2026 FCF Forecast
$4.75B
2027 FCF Forecast
$5.09B
2028 FCF Forecast
$5.36B
2029 FCF Forecast
$6.02B
2030 FCF Forecast
$6.40B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
CTLT Stock Forecast Catalent Outperform 15
$66.78 Buy/Sell $83.92 9.31%
IONS Stock Forecast Ionis Pharmaceuticals Outperform 9
$35.62 Buy/Sell $52.42 40.37%
CYTK Stock Forecast Cytokinetics Outperform 10
$36.17 Buy/Sell $62.67 65.88%

Vertex Pharmaceuticals Inc Net Income Forecast for 2023 - 2025 - 2030

In the last two years, Vertex Pharmaceuticals Inc's Net Income has increased by 99.02%, going from $1.18B to $2.34B. In the next year, analysts are expecting an increase in Net Income, predicting it will reach $4.05B – an increase of 73.10%. The Vertex Pharmaceuticals Inc forecast is for Net Income to reach $6.01B or grow by 156.57%.

2023 NI Forecast
$4.05B
2024 NI Forecast
$4.21B
2025 NI Forecast
$4.48B
2026 NI Forecast
$4.83B
2027 NI Forecast
$5.02B
2028 NI Forecast
$5.37B
2029 NI Forecast
$5.71B
2030 NI Forecast
$6.01B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
BCPC Stock Forecast Balchem Outperform 18
$127.30 Buy/Sell $163.67 28.83%
NEOG Stock Forecast Neogen Hold 16
$18.91 Buy/Sell $37.00 34.85%
CORT Stock Forecast Corcept Therapeutics Outperform 16
$21.25 Buy/Sell $0.00 38.82%

Vertex Pharmaceuticals Inc EBITDA Forecast for 2023 - 2025 - 2030

Vertex Pharmaceuticals Inc's EBITDA has increased by 121.91% In the last two years, going from $1.31B to $2.90B. In the next year, analysts expect EBITDA to reach $5.57B – an increase of 91.63%. For the next eight years, the forecast is for EBITDA to grow by 89.66%.

2023 EBITDA Forecast
$5.57B
2024 EBITDA Forecast
$5.94B
2025 EBITDA Forecast
$6.23B
2026 EBITDA Forecast
$5.01B
2027 EBITDA Forecast
$5.23B
2028 EBITDA Forecast
$5.50B
2029 EBITDA Forecast
$5.78B
2030 EBITDA Forecast
$5.51B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
TGTX Stock Forecast TG Therapeutics Outperform 9
$14.91 Buy/Sell $73.38 27.43%
INDV Stock Forecast Indivior PLC Buy 14
£179.50 Buy/Sell £3.79 -97.36%
PCRX Stock Forecast Pacira BioSciences Outperform 16
$40.28 Buy/Sell $79.67 93.64%

Vertex Pharmaceuticals Inc EBIT Forecast for 2023 - 2025 - 2030

In the last two years, Vertex Pharmaceuticals Inc's EBIT has grown, increasing from $1.20B to $2.78B – a growth of 131.20%. The next year looks promising for Vertex Pharmaceuticals Inc, with analysts predicting EBIT of $5.07B – an increase of 82.50%. Over the next eight years, experts anticipate that Vertex Pharmaceuticals Inc's EBIT will grow at a rate of 162.88%.

2023 EBIT Forecast
$5.07B
2024 EBIT Forecast
$5.18B
2025 EBIT Forecast
$5.44B
2026 EBIT Forecast
$5.82B
2027 EBIT Forecast
$6.20B
2028 EBIT Forecast
$6.57B
2029 EBIT Forecast
$6.92B
2030 EBIT Forecast
$7.31B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
AMPH Stock Forecast Amphastar Pharmaceuticals Outperform 14
$36.99 Buy/Sell $41.00 18.95%
IRWD Stock Forecast Ironwood Pharmaceuticals Hold 14
$10.59 Buy/Sell $12.60 18.04%
SUPN Stock Forecast Supernus Pharmaceuticals Outperform 16
$36.70 Buy/Sell $35.50 -7.36%

Vertex Pharmaceuticals Inc EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last two years, EPS for Vertex Pharmaceuticals Inc has grown by 144.28%, going from $5.33 to $13.02. In the coming year, analysts are expecting an increase in EPS, predicting it will reach $15.55 – an increase of 19.43%. Over the next eight years, experts anticipate that EPS growth for Vertex Pharmaceuticals Inc will be 74.58%.

2023 EPS Forecast
$15.55
2024 EPS Forecast
$16.12
2025 EPS Forecast
$17.38
2026 EPS Forecast
$18.64
2027 EPS Forecast
$19.13
2028 EPS Forecast
$20.32
2029 EPS Forecast
$21.47
2030 EPS Forecast
$22.73
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
LGND Stock Forecast Ligand Pharmaceuticals Outperform 14
$71.18 Buy/Sell $195.43 122.67%
MDGL Stock Forecast Madrigal Pharmaceuticals Outperform 4
$245.62 Buy/Sell $170.08 -28.75%
USNA Stock Forecast USANA Health Sciences Hold 14
$61.15 Buy/Sell $104.00 -6.79%